i made a list of the equivalents of bristol myers.he companies that wouldn't be hurt even if it turned out to be worse than i expected, giving the 24 hour news cycle blows everything out of proportion, we get new crisis every week you have to develop your own list of bristol myers list. maybe verizon, steady eddie. southern company, be ready to buy them when we get a market-wide sell off. based on exaggerated crisis that won't hurt. then step two, ask yourself is this event bad for all the earnings out there? when the egyptians were demonstrating in the early 2011, trying to kick out the dictator, a moment even the oil stocks, which benefitted from high prices, got knocked down along with everything else. curious, right? what a tremendous. >> buy buy buy. >> if you bought the oil down. you made a killing. so remember, when there is a big scary crisis in the globe that threatens to knock down the market like the sovereign debt crisis in europe, remember the bristol myers theory, ask what the heck has to do with the earnings of my stock

bristol-myers and gilead, merck, pfizer, gsk, abbot and rosche all cross products, their products in various ways in the hiv area or outside of the hiv area. and they're so often in bed with each other, back and forth, in some cases, one country will sell the drug in the united states and others will sell it in europe. or there might be a fixed dose combination that involves products from both in the united states, bristol-myers, and gillian. so it's hard to know, are they partners or are they competitors? and the prices would suggest they're more like partners than competitors. >> let me -- yes, dr. stiglitz. >> two comments i want to add. i think you were right in thinking about this as an experiment and thinking about how we can develop a better innovation system, not just for aids, but for health and beyond health for research more broadly. and i just wanted to reiterate that in thinking about the innovation system, there are a couple of other parts. the patent system will continue to play some role in, for instance, ideas that we haven't even thought about. in health, the price

lily, glaxosmithkline, bristol-myers and abbett, who has higher growth prospects according to you?t is splitting. that is the best one and next i would own bristol-myers, but i do prefer abbott, my charitable trust owns it. stay with "mad money."  >>> we had a classic journalism 101 question brewing here with this jpmorgan trade blow up. it's the four ys and a w, who, as in who was behind this bonehead trade. what, as in what was the trade really? we have no idea. where, meaning was this sovereign debt over there? the very stuff that we thought jpmorgan wasn't exposed to? when, as in when did ceo jamie dimon learn about the dimensions of this fiasco? because he was yapping around telling everyone this whale story of the outside position outside his london shop was just a tempest in teapot. so why, why did he just come out now? after speaking to analysts earlier this week, as well as david gregory from "meet the press" for sunday, and admit to this, huh, now? finally, how, as in how the heck could this happen given jamie dimon's endless preaching that he's the risk

lily, glaxosmithkline, bri bristol-myers and abbett, who has higher growth prospects according to you is splitting. that is the best one and next i would own bristol-myers, but i do prefer abbott, my charitable trust owns it. stay with "mad money." awesome!!! [ male announcer ] the spark business card from capital one. choose unlimited rewards with 2% cash back or double miles on every purchase, every day! what's in your wallet? how math and science kind of makes the world work. in high school, i had a physics teacher by the name of mr. davies. he made physics more than theoretical, he made it real for me. we built a guitar, we did things with electronics and mother boards. that's where the interest in engineering came from. so now, as an engineer, i have a career that speaks to that passion. thank you, mr. davies. welcome to the world leader in derivatives. welcome to superderivatives. >>> we had a classic journalism 101 question brewing here with this jpmorgan trade blow up. it's the four ys and a w, who, as in who was behind this bonehead trade. what, as in what was the trade reall

lily, glaxosmithkline, bristol-myers and abbett, who has higher growth prospects according to you? the best one and next i would own bristol-myers, but i do prefer abbott, my charitable trust owns it. stay with "mad money." ♪ so every year my family throws this great reunion in austin. but this year, i can only afford one trip and i've always wanted to learn how to surf. austin's great -- just not for surfing. so i checked out hotwire. and by booking with them, i saved enough to swing both trips. see, hotwire checks the competition's rates every day so they can guarantee their low prices. that's how i got a 4-star hotel on the beach in san diego for half price. ♪ h-o-t-w-i-r-e ♪ hotwire.com [ female announcer ] take the pantene dare to compare challenge. get healthier, stronger hair in 7 days guaranteed. then tell us your results on facebook. pantene healthier hair in less than 7 days. >>> we had a classic journalism 101 question brewing here with this jpmorgan trade blow up. it's the four ys and a w, who, as in who was behind this bonehead trade. what, as in what was the trade rea

i think you pick up a good health care name like bristol-myers squibb. it does have the dividend and you get a little cheaper today. so i like all those things. >> all right. thanks very much, jim. let's see how the bond market is reacting. that's one of the places that people have been putting their money, because of the financial mess in europe. we also have the results of the three-year note auction. rick santelli, you're up. how is the demand? >> the demand was very good. the auction 32 billion threes came in at a yield of .362. the w.i. market was right there at 1:00 eastern. it was 36 1/2 bid offered at 36. the bid to cover at 3.65's the best since january. and you're hard pressed to find another one in that region going back through time. 35.7 on indirects. very close to the ten auction average on 37. 11.2 on directs. 11 above the average of 10%. b-plus. dealers took down about 53%. very, very solid auction. back to you, tyler. >> all right, don't go anywhere. you're going to be outraged by what diana olick is reporting. that's about two minutes a

amylin already said no to bristol-myers squibb's $22 a share offer. don't except a deal for talbots. the women's clothing retailer ended buyout talks with its second largest shareholder, sycamore partners, sending the stock plummeting. shares lost 41% of their value, dropping below $2 per share. sycamore offered talbots $3.05 per share, more than double tonight's price. the firm said it remains open to a deal with the private equity firm can get financing and close the deal. with the end of these exclusive talks, talbots is free to look for other options. with europe in a recession and china slowing down, investors may be worried about global trade, but we saw stock buying of tanker and cargo ship companies. overseas ship-holding jumped almost 10%. ship-finance was up more than 9%. it's first quarter profits were up and it raised its dividend. front-line shipping gained 8%. overseas and front line shares have lost more than half their value in the past year. our e.t.f. market flash, the top five actively traded funds were all down. the biggest losses

maybe like a bristol myers or own hormel. own a food company. that would be a nice diversification.orida. >> caller: booyah from sunny palm beach, dr. cramer. >> i love palm beach. what's going on? >> caller: please tell me if i'm diversified. apple, baker hughes, cisco, intel, century link, ctl. >> okay. no. no. you got some real work to do here. century link, that's fine. that's a higher yielding slow growth telco. baker hughes, not great oil services company so you have oil services and telco. then you have these three. these are all in the same cohort, cisco, apple and intel. even though intel has had great yield, we'll sell intel and even though cisco is down on its luck and seems really cheap are we're going to sell cisco and keep apple. let's put honeywell in, that would be good to replace cisco and then maybe not all industrials, we'll go back and use the hormel example to replace intel and then i would feel -- but not yet. rich in california, please. >> caller: thanks very much for sharing your knowledge and that dirty linoleum floor with us. >> i hear you. what's up? >> ca

we're going to take out diageo and i'm going to put in bristol myers. that way i got a little pharmaceutical and that's going to give me the diversification i need and give me a higher yield than diageo. i want to go to louis in california. >> caller: good afternoon, dr. cramer. >> i didn't know i was a doctor. i'll take it. what's up? >> caller: thank you for your sage advice and education to us at-home investors. it's been really helpful, profitable and appreciated. >> that's what i want. i had a lot of people in new orleans who watch the show, felt terrific. what's going on? >> caller: i've been concentrating in high dividend stocks. as long as they can cover the dividend without getting into the capital. my biggest percentage of portfolio position is cplp, capital products limited partners, a ship leasing company. two, two harbors, a mortgage reit. >> right >> caller: p.e.r. then starbucks, i've been ringing the register a little bit lately. and then finally my spec trade is veco, a semiconductor equipment manufacturer. am i diversified? >> i am so

bristol-myers is the maker and the sales number is expected to decrease drastically after it goes offt. >>> and facebook's ipo, facebook has filed to increase the size of its ipo by 422 million shares, a 25% jump. this means the deal could raise as much as $18.5 billion. >>> also taking a look at apple, wondering what the next generation iphone will look like? one thing we do no is apple has ordered larger display screens from its asian suppliers. people familiar with the situation say they measure at least four inches diagonally. compared with the current three and a half inches on the iphone 4s. back to you. >> seema, thank you so much. >>> the birth of a baby can trigger powerful emotions from excitement and joy to fear and anxiety. but it can also result in something you might not expect. and that's depression. in fact, one in eight women will develop postpartum depression after giving birth. dr. skbrosh waugh winer is hee to explain why and how it can be treated. why don't you explain the difference between baby blues and postpartum depression? >> so baby blues is this moodiness,

now bristol-myers top selling drug. you see shares a penny higher right now. seema mody's on the pharma beat. >> last quarter plavix brought in about a fifth of bristol's total revenue. but sales are expected to plunge after the blood thinner goes off patent and lower cost generics become available. analysts at isi group tell me they estimate a 40% drop in quarterly sales. so to compensate, bristol has been working to develop the next blockbuster drug. at the top of its list, an experimental drug thinner awaiting fda decision in late june. bristol among several players competing to launch new hepatitis c treatments recently making a $2.5 billion acquisition. bristol is on a spending spree buying up promising early to mid-stage sized biotech firms. analysts say future acquisitions will most likely be in the cancer and immunology space. all in all, tyler, bristol is hoping its strong pipeline and series of smart acquisitions will carry the company through the losses of plavix. back to you. >>> matt cheslock back with me. matt, how are you playing specifically the

clax o, bristol myers, common drugs to treat common conditions and investors have made big bets basedare disease fighters a possible good bet for your money? seema mody on the pharma beat. >> that's right, tyler. pfizer thinks so. in an effort to deal with the loss, pfizer is presenting a drug to a panel that advises the fda. it treats a rare genetic disease that impacts a small patient pool of 8,000 people worldwide. yes, limited customer base, but pfizer could essentially own a piece of what could be a lucrative market. a trend we witnessed in the pharma space, getting that first-mover advantage allows the drug giants to dictate pricing. while the advisory panel will make their decision tomorrow, the fda has already expressed a lot of concern around this drug. but pfizer telling cnbc that its data provides substantial evidence that support an approval. ahead of that meeting the stock trading in negative territory. sue, over to you. >> thank you very much, seema. so let's bring in jeff. you know, the markets -- i'm just looking up at the board, we're off of our worst levels, but we'r

put it in bristol myers trust.stol myers. >> why do you think buffet says buy american i am and the best is a house with a 30 year mortgage. >> i couldn't agree more. i'm trying to buy as many houses as he has. i don't have his fire power. >> this is what you should do instead of buying treasuries. >> certainly better than the german bun today. 1436. >> they've got to make it able so they can exploit everybody education else on the continent. hey, we bit the bullet when we bought eastern germany. >> let's check out what else is moving? >> this may be our first day of trade. remember, europe is one day ahead of us. those bank issues just continue to fall. still not sure exactly what the end all, be all solution will be. and take a look at that risk premium. this is hitting euro area highs. this is the highest that we've soon since the euro was created the first time with 500 base points happening yesterday. and we're hitting that again today. today, that ten-year getting closer to 7 prnt p%. but if you move states,

bristol-myers and gilead, merck, pfizer, gsk, ab ott and roche all cross-license their products in various hiv area. and -- or outside of the hiv area. and they're so often in bed with each other back and forth, in some cases one company will sell the drug in the united states, another country will sell it in europe or other countries or there might be be a fixed-dose combination by the leading one involves products from both in the united states bristol-myers and gilead. so it's hard to know are they partners, or are they competitors? and the prices would suggest they're more like partners than competitors. >> all right. let me -- yeah, dr. stiglitz. >> just two comments i want to add. you, i think, were right in thinking about this as an experiment, an innovation innovation. and thinking about how we can develop a better innovation system not just for aids, but for health and beyond health for research more broadly. and i just want to reiterate that in thinking about the innovation system, there are a couple of other parts. the patent system will continue to play some role in, for instan